NCT07255963

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

A Prospective Study of Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.

Conditions

• DLBCL - Diffuse Large B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	200mg qd po
DRUG	Lisaftoclax	cycle 1: 200mg qd d1-7; 400mg qd d8-d28；Cycle 2: 400mg qd d1-d28 po
DRUG	Rituximab	375mg/m2 d1 intravenous drip

Timeline

• Start date: 2025-11-30
• Primary completion: 2028-09-30
• Completion: 2030-09-30
• First posted: 2025-12-01
• Last updated: 2025-12-01

Locations

1 site across 1 country: China